No Effect of serotoninergic gene variants on response to interpersonal counseling and antidepressants in major depression

Psychiatry Investigation

Volumn 10, Issue 2, 2013, Pages 180-189

  Serretti, Alessandro ^a   Fabbri, Chiara ^a   Pellegrini, Silvia ^b   Porcelli, Stefano ^a   Politi, Pierluigi ^c   Bellino, Silvio ^d   Menchetti, Marco ^a   Mariotti, Veronica ^b   Demi, Cristina ^b   Martinelli, Valentina ^c   Cappucciati, Marco ^c   Bozzatello, Paola ^d   Brignolo, Elena ^d   Brambilla, Paolo ^e   Pae, Chi Un ^f,g   Balestrieri, Matteo ^e   DeRonchi, Diana ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF PISA   (Italy)

^c UNIVERSITY OF PAVIA   (Italy)

^d UNIVERSITY OF TURIN   (Italy)

^e UNIVERSITY OF VERONA   (Italy)

^f The Catholic University of Korea   (South Korea)

^g DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

5 HT; 5 HT1A Receptor; 5 HT2A Receptor; Antidepressants; COMT; Genes; Major depression; Polymorphism; Psychotherapy; Serotonin transporter

Indexed keywords

ANTIDEPRESSANT AGENT; SEROTONIN;

ADULT; ARTICLE; COGNITIVE DEFECT; COUNSELING; DISEASE SEVERITY; FEMALE; GENETIC ASSOCIATION; GENOTYPE; HUMAN; INTERPERSONAL COUNSELING; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MINI MENTAL STATE EXAMINATION; PROTEIN POLYMORPHISM; REMISSION; TREATMENT OUTCOME;

EID: 84879382430     PISSN: 17383684     EISSN: 19763026     Source Type: Journal    
DOI: 10.4306/pi.2013.10.2.180     Document Type: Article

References (56)

1. Alonso J, Angermeyer MC, Bernert S, Bruffaerts R, Brugha TS, Bryson H, et al. Disability and quality of life impact of mental disorders in Europe: results from the European Study of the Epidemiology of Mental Disorders (ESEMeD) project. Acta Psychiatr Scand Suppl 2004;(420): 38-46.
2. Trivedi MH, Rush AJ, Wisniewski SR, Nierenberg AA, Warden D, Ritz L, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry 2006;163:28-40.
3. Unutzer J, Park M. Strategies to improve the management of depression in primary care. Prim Care 2012;39:415-431.
4. Busch FN, Sandberg LS. Combined treatment of depression. Psychiatr Clin North Am 2012;35:165-179.
5. Frank E, Cassano GB, Rucci P, Thompson WK, Kraemer HC, Fagiolini A, et al. Predictors and moderators of time to remission of major depression with interpersonal psychotherapy and SSRI pharmacotherapy. Psychol Med 2011;41:151-162.
6. Porcelli S, Drago A, Fabbri C, Gibiino S, Calati R, Serretti A. Pharmacogenetics of antidepressant response. J Psychiatry Neurosci 2011;36: 87-113.
7. Ban TA. Pharmacotherapy of depression: a historical analysis. J Neural Transm 2001;108:707-716.
8. Burnet PW, Eastwood SL, Lacey K, Harrison PJ. The distribution of 5-HT1A and 5-HT2A receptor mRNA in human brain. Brain Res 1995; 676:157-168.
9. Landen M, Thase ME. A model to explain the therapeutic effects of serotonin reuptake inhibitors: the role of 5-HT2 receptors. Psychopharmacol Bull 2006;39:147-166.
10. McMahon FJ, Buervenich S, Charney D, Lipsky R, Rush AJ, Wilson AF, et al. Variation in the gene encoding the serotonin 2A receptor is associated with outcome of antidepressant treatment. Am J Hum Genet 2006;78:804-814.
11. Peters EJ, Slager SL, Jenkins GD, Reinalda MS, Garriock HA, Shyn SI, et al. Resequencing of serotonin-related genes and association of tagging SNPs to citalopram response. Pharmacogenet Genomics 2009;19: 1-10.
12. Horstmann S, Lucae S, Menke A, Hennings JM, Ising M, Roeske D, et al. Polymorphisms in GRIK4, HTR2A, and FKBP5 show interactive effects in predicting remission to antidepressant treatment. Neuropsychopharmacology 2010;35:727-740.
13. Perlis RH, Fijal B, Adams DH, Sutton VK, Trivedi MH, Houston JP. Variation in catechol-O-methyltransferase is associated with duloxetine response in a clinical trial for major depressive disorder. Biol Psychiatry 2009;65:785-791.
14. Uher R, Huezo-Diaz P, Perroud N, Smith R, Rietschel M, Mors O, et al. Genetic predictors of response to antidepressants in the GENDEP project. Pharmacogenomics J 2009;9:225-233.
15. Kishi T, Yoshimura R, Kitajima T, Okochi T, Okumura T, Tsunoka T, et al. HTR2A is associated with SSRI response in major depressive disorder in a Japanese cohort. Neuromolecular Med 2010;12:237-242.
16. Illi A, Setala-Soikkeli E, Viikki M, Poutanen O, Huhtala H, Mononen N, et al. 5-HTR1A, 5-HTR2A, 5-HTR6, TPH1 and TPH2 polymorphisms and major depression. Neuroreport 2009;20:1125-1128.
17. Lucae S, Ising M, Horstmann S, Baune BT, Arolt V, Muller-Myhsok B, et al. HTR2A gene variation is involved in antidepressant treatment response. Eur Neuropsychopharmacol 2010;20:65-68.
18. Viikki M, Huuhka K, Leinonen E, Illi A, Setala-Soikkeli E, Huuhka M, et al. Interaction between two HTR2A polymorphisms and gender is associated with treatment response in MDD. Neurosci Lett 2011;501: 20-24.
19. McAuley EZ, Fullerton JM, Blair IP, Donald JA, Mitchell PB, Schofield PR. Association between the serotonin 2A receptor gene and bipolar affective disorder in an Australian cohort. Psychiatr Genet 2009;19:244-252.
20. Albert PR, Lemonde S. 5-HT1A receptors, gene repression, and depression: guilt by association. Neuroscientist 2004;10:575-593.
21. Lemonde S, Turecki G, Bakish D, Du L, Hrdina P, Bown C, et al. Impaired repression at a 5-hydroxytryptamine 1A receptor gene polimorphism associated with major depression and suicide. J Neurosci 2003; 23:8788-8799.
22. Arias B, Catalan R, Gasto C, Gutierrez B, Fananas L. Evidence for a combined genetic effect of the 5-HT(1A) receptor and serotonin transporter genes in the clinical outcome of major depressive patients treated with citalopram. J Psychopharmacol 2005;19:166-172.
23. Hong CJ, Chen TJ, Yu YW, Tsai SJ. Response to fluoxetine and serotonin 1A receptor (C-1019G) polymorphism in Taiwan Chinese major depressive disorder. Pharmacogenomics J 2006;6:27-33.
24. Kato M, Fukuda T, Wakeno M, Okugawa G, Takekita Y, Watanabe S, et al. Effect of 5-HT1A gene polymorphisms on antidepressant response in major depressive disorder. Am J Med Genet B Neuropsychiatr Genet 2009;150B:115-123.
25. Lemonde S, Du L, Bakish D, Hrdina P, Albert PR. Association of the C(-1019)G 5-HT1A functional promoter polymorphism with antidepressant response. Int J Neuropsychopharmacol 2004;7:501-506.
26. Parsey RV, Olvet DM, Oquendo MA, Huang YY, Ogden RT, Mann JJ. Higher 5-HT1A receptor binding potential during a major depressive episode predicts poor treatment response: preliminary data from a naturalistic study. Neuropsychopharmacology 2006;31:1745-1749.
27. Serretti A, Artioli P, Lorenzi C, Pirovano A, Tubazio V, Zanardi R. The C(-1019)G polymorphism of the 5-HT1A gene promoter and antidepressant response in mood disorders: preliminary findings. Int J Neuropsychopharmacol 2004;7:453-460.
28. Villafuerte SM, Vallabhaneni K, Sliwerska E, McMahon FJ, Young EA, Burmeister M. SSRI response in depression may be influenced by SNPs in HTR1B and HTR1A. Psychiatr Genet 2009;19:281-291.
29. Levin GM, Bowles TM, Ehret MJ, Langaee T, Tan JY, Johnson JA, et al. Assessment of human serotonin 1A receptor polymorphisms and SSRI responsiveness. Mol Diagn Ther 2007;11:155-160.
30. Lin E, Chen PS, Chang HH, Gean PW, Tsai HC, Yang YK, et al. Interaction of serotonin-related genes affects short-term antidepressant response in major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry 2009;33:1167-1172.
31. Noro M, Antonijevic I, Forray C, Kasper S, Kocabas NA, Lecrubier Y, et al. 5HT1A and 5HT2A receptor genes in treatment response phenotypes in major depressive disorder. Int Clin Psychopharmacol 2010; 25:228-231.
32. Peters EJ, Slager SL, McGrath PJ, Knowles JA, Hamilton SP. Investigation of serotonin-related genes in antidepressant response. Mol Psychiatry 2004;9:879-889.
33. Yu YW, Tsai SJ, Liou YJ, Hong CJ, Chen TJ. Association study of two serotonin 1A receptor gene polymorphisms and fluoxetine treatment response in Chinese major depressive disorders. Eur Neuropsychopharmacol 2006;16:498-503.
34. Wray NR, James MR, Gordon SD, Dumenil T, Ryan L, Coventry WL, et al. Accurate, large-scale genotyping of 5HTTLPR and flanking single nucleotide polymorphisms in an association study of depression, anxiety, and personality measures. Biol Psychiatry 2009;66:468-476.
35. Weinshilboum RM, Otterness DM, Szumlanski CL. Methylation pharmacogenetics: catechol O-methyltransferase, thiopurine methyltransferase, and histamine N-methyltransferase. Annu Rev Pharmacol Toxicol 1999;39:19-52.
36. Arias B, Serretti A, Lorenzi C, Gasto C, Catalan R, Fananas L. Analysis of COMT gene (Val 158 Met polymorphism) in the clinical response to SSRIs in depressive patients of European origin. J Affect Disord 2006; 90:251-256.
37. Baune BT, Hohoff C, Berger K, Neumann A, Mortensen S, Roehrs T, et al. Association of the COMT val158met variant with antidepressant treatment response in major depression. Neuropsychopharmacology 2008;33:924-932.
38. Benedetti F, Colombo C, Pirovano A, Marino E, Smeraldi E. The catechol-O-methyltransferase Val(108/158)Met polymorphism affects antidepressant response to paroxetine in a naturalistic setting. Psychopharmacology (Berl) 2009;203:155-160.
39. Szegedi A, Rujescu D, Tadic A, Muller MJ, Kohnen R, Stassen HH, et al. The catechol-O-methyltransferase Val108/158Met polymorphism affects short-term treatment response to mirtazapine, but not to paroxetine in major depression. Pharmacogenomics J 2005;5:49-53.
40. Tsai SJ, Gau YT, Hong CJ, Liou YJ, Yu YW, Chen TJ. Sexually dimorphic effect of catechol-O-methyltransferase val158met polymorphism on clinical response to fluoxetine in major depressive patients. J Affect Disord 2009;113:183-187.
41. Yoshida K, Higuchi H, Takahashi H, Kamata M, Sato K, Inoue K, et al. Influence of the tyrosine hydroxylase val81met polymorphism and catechol-O-methyltransferase val158met polymorphism on the antidepressant effect of milnacipran. Hum Psychopharmacol 2008;23:121-128.
42. Beck AR, B. Shaw, G. Emery. Cognitive Therapy of Depression. New York: Guildford Press; 1988.
43. Simons AD, Garfield SL, Murphy GE. The process of change in cognitive therapy and pharmacotherapy for depression. Changes in mood and cognition. Arch Gen Psychiatry 1984;41:45-51.
44. Lehto SM, Tolmunen T, Joensuu M, Saarinen PI, Valkonen-Korhonen M, Vanninen R, et al. Changes in midbrain serotonin transporter availability in atypically depressed subjects after one year of psychotherapy. Prog Neuropsychopharmacol Biol Psychiatry 2008;32:229-237.
45. Linden DE. How psychotherapy changes the brain--the contribution of functional neuroimaging. Mol Psychiatry 2006;11:528-538.
46. Menchetti M, Bortolotti B, Rucci P, Scocco P, Bombi A, Berardi D, et al. Depression in primary care: interpersonal counseling vs selective serotonin reuptake inhibitors. The DEPICS Study. A multicenter randomized controlled trial. Rationale and design. BMC Psychiatry 2010;10:97.
47. Judd FK, Piterman L, Cockram AM, McCall L, Weissman MM. A comparative study of venlafaxine with a focused education and psychotherapy program versus venlafaxine alone in the treatment of depression in general practice. Hum Psychopharmacol 2001;16:423-428.
48. Neugebauer R, Kline J, Bleiberg K, Baxi L, Markowitz JC, Rosing M, et al. Preliminary open trial of interpersonal counseling for subsyndromal depression following miscarriage. Depress Anxiety 2007;24:219-222.
49. Holmes A, Hodgins G, Adey S, Menzel S, Danne P, Kossmann T, et al. Trial of interpersonal counselling after major physical trauma. Aust N Z J Psychiatry 2007;41:926-933.
50. Oranta O, Luutonen S, Salokangas RK, Vahlberg T, Leino-Kilpi H. The outcomes of interpersonal counselling on depressive symptoms and distress after myocardial infarction. Nord J Psychiatry 2010;64:78-86.
51. Weissman M. Interpersonal Counselling for Stress and Distress in Primary Care: A Treatment Manual. New York: Columbia University;1988.
52. Serretti A, Chiesa A, Calati R, Perna G, Bellodi L, De Ronchi D. Common genetic, clinical, demographic and psychosocial predictors of response to pharmacotherapy in mood and anxiety disorders. Int Clin Psychopharmacol 2009;24:1-18.
53. Meyers BS, Sirey JA, Bruce M, Hamilton M, Raue P, Friedman SJ, et al. Predictors of early recovery from major depression among persons admitted to community-based clinics: an observational study. Arch Gen Psychiatry 2002;59:729-735.
54. Kilts CD, Wade AG, Andersen HF, Schlaepfer TE. Baseline severity of depression predicts antidepressant drug response relative to escitalopram. Expert Opin Pharmacother 2009;10:927-936.
55. Pitychoutis PM, Zisaki A, Dalla C, Papadopoulou-Daifoti Z. Pharmacogenetic insights into depression and antidepressant response: does sex matter? Curr Pharm Des 2010;16:2214-2223.
56. Zaman R. Psychological treatments and brain plasticity. Psychiatr Danub 2010;22(Suppl 1):S6-S9.